<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">34780883</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.</ArticleTitle><Pagination><MedlinePgn>198629</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(21)00336-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2021.198629</ELocationID><Abstract><AbstractText>The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1+L249S+E484K lineage was isolated along with A.1, B.1.420 and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the neutralizing titer of convalescent sera was compared using microneutralization assays. While no significant differences in the neutralizing antibody titers were found between A1 and B lineages without the E484K mutation, the neutralizing titers against B.1+L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular epidemiological data indicate that there is no increase in the transmissibility rate associated with this new lineage. This study supports the capability of new variants with the E484K mutation to be resistant to neutralization by humoral immunity, and therefore the need to intensify surveillance programs to determine if these lineages represent a risk for the public health.</AbstractText><CopyrightInformation>Copyright © 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Álvarez-Díaz</LastName><ForeName>Diego A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Grupo de Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laiton-Donato</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Grupo de Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-García</LastName><ForeName>Orlando Alfredo</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Faculty of Veterinary Medicine and Zootechnics, Universidad Antonio Nariño, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Moreno</LastName><ForeName>Hector Alejandro</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Grupo de Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Muñoz</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia; Grupo de Parasitología. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltran</LastName><ForeName>Maria Angie</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercado-Reyes</LastName><ForeName>Marcela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grupo de Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueda</LastName><ForeName>Miguel Germán</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muñoz</LastName><ForeName>Ana Luisa</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia; Faculty of Science, Universidad Antonio Nariño, Bogotá, Colombia. Electronic address: ana.munoz@hemolfeamerica.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">E484K mutation</Keyword><Keyword MajorTopicYN="N">Neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 lineages</Keyword><Keyword MajorTopicYN="N">Spike protein</Keyword><Keyword MajorTopicYN="N">Variant of Interest</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34780883</ArticleId><ArticleId IdType="pii">S0168-1702(21)00336-1</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2021.198629</ArticleId><ArticleId IdType="pmc">PMC8585963</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell. 2021 Apr 29;184(9):2384-2393.e12</Citation><ArticleIdList><ArticleId IdType="pubmed">33794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2021 Feb;18(2):318-327</Citation><ArticleIdList><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccines (Basel). 2021 Apr 15;9(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">33920999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Aug 20;182(4):812-827.e19</Citation><ArticleIdList><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2021 Jul 23;433(15):167058</Citation><ArticleIdList><ArticleId IdType="pubmed">34023401</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccines (Basel). 2020 Dec 28;9(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">33379160</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2021 Aug;27(8):1109-1117</Citation><ArticleIdList><ArticleId IdType="pubmed">34015535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Oct 29;183(3):739-751.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32991842</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2021 Sep;93:104941</Citation><ArticleIdList><ArticleId IdType="pubmed">34044192</ArticleId></ArticleIdList></Reference><Reference><Citation>Signal Transduct Target Ther. 2021 Feb 26;6(1):95</Citation><ArticleIdList><ArticleId IdType="pubmed">33637679</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Microbiol. 2020 Nov;5(11):1403-1407</Citation><ArticleIdList><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2021 Apr;592(7852):116-121</Citation><ArticleIdList><ArticleId IdType="pubmed">33106671</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2021 Nov;95:105038</Citation><ArticleIdList><ArticleId IdType="pubmed">34403832</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Med Res. 2020 Jul &amp; Aug;152(1 &amp; 2):82-87</Citation><ArticleIdList><ArticleId IdType="pubmed">32859866</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2021 Aug 6;373(6555):648-654</Citation><ArticleIdList><ArticleId IdType="pubmed">34210893</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2020 Dec;26(12):2854-2862</Citation><ArticleIdList><ArticleId IdType="pubmed">33219646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2021 Sep;597(7878):703-708</Citation><ArticleIdList><ArticleId IdType="pubmed">34428777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2021 Jan 7;184(1):64-75.e11</Citation><ArticleIdList><ArticleId IdType="pubmed">33275900</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Microbiol. 2020 Sep 04;11:2020</Citation><ArticleIdList><ArticleId IdType="pubmed">33013745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Microbe. 2021 Jul;2(7):e283-e284</Citation><ArticleIdList><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2021 Jul;19(7):409-424</Citation><ArticleIdList><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 2020;2099:107-116</Citation><ArticleIdList><ArticleId IdType="pubmed">31883091</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Med (Lausanne). 2021 Jun 28;8:697605</Citation><ArticleIdList><ArticleId IdType="pubmed">34262921</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2021 Apr 21;13(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">33919314</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2021 May;27(5):917-924</Citation><ArticleIdList><ArticleId IdType="pubmed">33772244</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2021 Mar 10;16(3):e0248348</Citation><ArticleIdList><ArticleId IdType="pubmed">33690649</ArticleId></ArticleIdList></Reference><Reference><Citation>Brief Bioinform. 2019 Jul 19;20(4):1160-1166</Citation><ArticleIdList><ArticleId IdType="pubmed">28968734</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2020 Nov;85:104557</Citation><ArticleIdList><ArticleId IdType="pubmed">32950697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>